Search Results
Search here to find what you are looking for. If you are searching for a Teva product, you may want to try searching in one of our product catalogues or feel free to contact us for assistance.
Showing 10 from 14 results
Teva Canada announces the Approval of HERZUMA®, a biosimilar to HERCEPTIN® for the treatment of adult patients with Early Breast Cancer, Metastatic Breast Cancer and Metastatic Gastric Cancer.
This is the second Notice of Compliance (NOC) issued for a biosimilar in 2019 that Teva Canada Innovation will add to its portfolio of brands, generics and biosimilars.